The form was uploaded to medical-data-models.org - Original URL: https://medical-data-models.org/31306
StudyName: Iodine 131 B1 Antibody for B-Cell Lymphomas NCT00950755
Date of export from the portal: 02.07.2020
Copyright Holder: see clinicaltrials.gov
Date of Upload / last change: 12.08.2018
License: Creative Commons BY 4.0

----

Description: 
Study ID: 104505
Clinical Study ID: BEX104505
Study Title: Phase II Study of Iodine 131 Anti B1 Antibody for 1st or 2nd Relapsed Indolent B-Cell Lymphomas or B-Cell Lymphomas That Have Transformed to a More Aggressive Histology
Patient Level Data: Study Listed on ClinicalStudyDataRequest.com
Clinicaltrials.gov Identifier: NCT00950755
Sponsor: GlaxoSmithKline
Collaborators: N/A
Phase: Phase 2
Study Recruitment Status: Completed
Generic Name: tositumomab
Trade Name: Bexxar
Study Indication: Lymphoma, Non-Hodgkin

Any adverse experience is defined as a new or worsening pre-existing medical condition or complication occurring while on study, regardless of its perceived relationship to the drug.
Please record all adverse experiences from the time of study entry through the Week 13 visit.
